Be a part of 7th International Conference on Cancer Therapy

Precision oncology is transforming cancer treatment by matching therapies to the molecular characteristics of individual tumors. This session will explore genomic profiling, molecular classification, biomarkers, pharmacogenomics, companion diagnostics, and personalized treatment strategies. Discussions will focus on integrating genomic information into clinical decision-making, identifying actionable mutations, improving therapeutic response, and overcoming challenges associated with precision medicine implementation across different cancer types and healthcare settings.

• Track 2-1: Cancer Genomics & Molecular Profiling
• Track 2-2: Biomarker-Driven Personalized Treatment
• Track 2-3: Pharmacogenomics & Companion Diagnostics

This session focuses on innovative therapeutic approaches designed to improve cancer treatment efficacy and overcome limitations of conventional therapies. Topics will include targeted therapies, antibody-drug conjugates, bispecific antibodies, novel small molecules, combination treatments, and emerging drug platforms. Researchers and clinicians will discuss therapeutic development from discovery and preclinical evaluation to clinical trials, mechanisms of action, treatment resistance, safety considerations, and strategies for translating promising discoveries into effective cancer therapies.

• Track 3-1: Targeted Therapies & Novel Drug Targets
• Track 3-2: Antibody-Drug Conjugates & Bispecific Antibodies
• Track 3-3: Next-Generation Cancer Drug Development

Immunotherapy has become a major pillar of modern cancer treatment. This session will examine advances in immune checkpoint inhibitors, cancer vaccines, adoptive immune therapies, immune biomarkers, and combination approaches. Presentations will address mechanisms of immune activation, primary and acquired resistance, immune-related adverse events, and strategies for expanding immunotherapy benefits across tumor types. The session will also explore emerging approaches designed to enhance durable immune responses and improve outcomes for patients with advanced cancers.

• Track 4-1: Immune Checkpoint Inhibitors & Combination Therapy
• Track 4-2: Cancer Vaccines & Tumor Immunology
• Track 4-3: Immune Biomarkers & Resistance Mechanisms

Cell and gene therapies are opening new possibilities for treating cancers that remain difficult to manage using conventional approaches. This session will highlight CAR-T cell therapy, T-cell receptor therapies, engineered immune cells, gene editing, and next-generation cellular platforms. Discussions will cover therapeutic efficacy, patient selection, manufacturing challenges, toxicity management, resistance, and approaches for expanding these treatments beyond hematological malignancies into solid tumors.

• Track 5-1: CAR-T, TCR & Engineered Cell Therapies
• Track 5-2: Gene Editing & Next-Generation Cell Therapy
• Track 5-3: Solid Tumor Applications & Treatment Resistance

Metastasis remains one of the greatest challenges in cancer management and is responsible for a significant proportion of cancer-related mortality. This session examines the molecular and cellular mechanisms driving tumor invasion, dissemination, metastatic colonization, and disease progression. Particular attention will be given to tumor–microenvironment interactions, circulating tumor cells, metastatic niches, immune regulation, and therapeutic strategies aimed at preventing or controlling metastatic disease and treatment resistance.

• Track 6-1: Tumor Invasion, Metastasis & Dissemination
• Track 6-2: Tumor Microenvironment & Metastatic Niches
• Track 6-3: Metastatic Disease & Therapeutic Resistance

Liquid biopsy is transforming cancer diagnosis and treatment monitoring by enabling minimally invasive molecular analysis. This session will explore circulating tumor DNA, circulating tumor cells, extracellular vesicles, molecular biomarkers, and genomic signatures. Applications in early detection, minimal residual disease assessment, treatment selection, response monitoring, and recurrence prediction will be discussed. The session will also address analytical challenges, clinical validation, standardization, and the integration of liquid biopsy into precision oncology.

• Track 7-1: Circulating Tumor DNA & Circulating Tumor Cells
• Track 7-2: Biomarkers for Early Detection & Treatment Monitoring
• Track 7-3: Minimal Residual Disease & Molecular Surveillance

Artificial intelligence and digital technologies are increasingly influencing cancer diagnosis, treatment planning, research, and patient management. This session will examine machine learning, predictive analytics, AI-assisted diagnosis, digital pathology, clinical decision-support systems, and computational oncology. Discussions will explore how these technologies can improve diagnostic accuracy, identify treatment responses, personalize therapeutic decisions, and optimize clinical workflows while addressing issues of data quality, validation, ethics, interoperability, and responsible implementation.

• Track 8-1: AI & Machine Learning in Cancer Diagnosis
• Track 8-2: Digital Pathology, Imaging & Predictive Analytics
• Track 8-3: AI-Driven Treatment Planning & Clinical Decision Support

Advanced imaging technologies and radiation techniques are enabling increasingly precise cancer diagnosis and treatment. This session will explore PET/CT, MRI, molecular imaging, radiomics, image-guided radiotherapy, adaptive radiation, stereotactic techniques, and proton therapy. Researchers will discuss how quantitative imaging and artificial intelligence can support tumor characterization, treatment planning, response assessment, and personalized radiation strategies while minimizing toxicity and improving outcomes across a range of malignant diseases.

• Track 9-1: Advanced Cancer Imaging & Molecular Imaging
• Track 9-2: Radiomics & AI-Enabled Imaging
• Track 9-3: Precision Radiation Therapy & Proton Therapy

Nanomedicine is creating new opportunities for precision cancer diagnosis, drug delivery, and treatment. This session will focus on nanoparticles, nanocarriers, targeted delivery systems, theranostics, controlled drug release, and nanotechnology-enabled diagnostics. Discussions will explore how nanotechnology can improve drug stability, enhance tumor targeting, overcome biological barriers, reduce systemic toxicity, and support personalized treatment. Emerging translational applications and challenges in clinical development will also be addressed.

• Track 10-1: Nanoparticle-Based Cancer Therapeutics
• Track 10-2: Targeted & Controlled Drug Delivery
• Track 10-3: Nanodiagnostics, Theranostics & Translational Nanomedicine

Early detection and prevention remain essential to reducing the global burden of cancer. This session will examine cancer risk factors, screening technologies, hereditary cancer assessment, lifestyle interventions, early diagnostic strategies, and population-based prevention programs. It will also address survivorship and long-term patient care, including recurrence monitoring, rehabilitation, psychosocial support, quality of life, and strategies for helping cancer survivors achieve healthier long-term outcomes.

• Track 11-1: Cancer Prevention, Risk Reduction & Hereditary Cancer
• Track 11-2: Early Detection, Screening & Diagnostic Innovation
• Track 11-3: Cancer Survivorship, Rehabilitation & Quality of Life

This session addresses the global challenges affecting access to effective cancer prevention, diagnosis, treatment, and survivorship services. It will explore healthcare disparities, affordable treatment, access to innovative therapies, multidisciplinary care, patient-centered approaches, and cancer policy. Particular emphasis will be placed on international collaboration, strengthening oncology infrastructure, improving outcomes in underserved populations, and developing sustainable strategies that enable equitable delivery of high-quality cancer care worldwide.

• Track 12-1: Global Cancer Disparities & Health Equity
• Track 12-2: Global Cancer Disparities & Health Equity
• Track 12-3: Cancer Policy, Access & International Collaboration